Advertisement

Development of radiogallium–ethylenecysteamine cysteine complex as a possible renal imaging agent

  • Amir Reza Jalilian
  • Hassan Yousefnia
  • Samaneh Zolghadri
  • Mohammad Reza Khoshdel
  • Fatemeh Bolourinovin
  • Ali Rahiminejad
Article

Abstract

[67Ga]-ethylenecysteamine cysteine ([67Ga]ECC) was prepared using freshly prepared [67Ga]GaCl3 and ethylenecysteamine cysteine (ECC) for 30 min at 90 °C (radiochemical purity ≈97 ± 0.88% ITLC, specific activity: 210 ± 5 GBq/mM). Stability of the complex was checked in human serum for 24 h at 37 °C. Partition co-efficient of the tracer in octanol:saline mixture was determined (log P; 0.8). The biodistribution of the radiolabeled compound in vital organs of wild-type rats were compared with that of free Ga3+ cation up to 48 h. Initial biodistribution results showed significant kidney excretion of the tracer comparable to that of homologous 99mTc compound.

Keywords

67Ga-complexation Ethylenecysteamine cysteine Biodistribution Renal agent 

Notes

Acknowledgements

Authors wish to thank Ms S. Moradkhani and Mr S. Daneshvari for conducting animal studies.

References

  1. 1.
    Firestone RB, Shirley VS, Baglin CM, Zipkin J (1996) Table of isotopes, 8th edn. Wiley, New York, p 1447Google Scholar
  2. 2.
    Henze M, Schuhmacher J, Hipp P, Kowalski JD, Becker DW, Doll J, Maecke HR, Hofmann M, Debus J, Haberkorn U (2001) J Nucl Med 42:1053Google Scholar
  3. 3.
    Froidevaux S, Heppeler A, Eberle AN, Meier AM, Hausler M, Beglinger C, Behe M, Powell P, Macke HR (2000) Endocrinology 141:3304CrossRefGoogle Scholar
  4. 4.
    Weiner RE (1996) Nucl Med Biol 23(6):745. (Review). doi: 10.1016/0969-8051(96)00119-9
  5. 5.
    Cutler CS, Giron MC, Reichert DE, Snyder AZ, Herrero P, Anderson CJ, Quarless DA, Koch SA, Welch MJ (1999) Nucl Med Biol 26:305CrossRefGoogle Scholar
  6. 6.
    Tsang BW, Mathias CJ, Green MA (1993) J Nucl Med 34:1127Google Scholar
  7. 7.
    Sharma V, Prior JL, Belinsky MG, Kruh GD, Piwnica-Worms D (2005) J Nucl Med 46(2):354Google Scholar
  8. 8.
    Jalilian AR, Mehdipour P, Akhlaghi M, Yousefnia H, Shafaii K (2009) Sci Pharm 77:343Google Scholar
  9. 9.
    Haghighi Moghadam F, Jalilian AR, Nemati A, Abedini M (2007) J Radioanal Nucl Chem 272:115CrossRefGoogle Scholar
  10. 10.
    Anderson CJ, John CS, Li YJ, Hancock RD, McCarthy TJ, Martell AE, Welch MJ (1995) Nucl Med Biol 22(2):165CrossRefGoogle Scholar
  11. 11.
    Li Y, Martell AE, Hancock RD, Reibenspies JH, Anderson CJ, Welch MJ (1996) Inorg Chem 35:404CrossRefGoogle Scholar
  12. 12.
    Vanbilloen HP, Cleynhens BJ, Verbruggen AM (2000) Nucl Med Biol 27:207CrossRefGoogle Scholar
  13. 13.
    Blondeau P, Berse C, Gracel D (1967) Can J Chem 45:49CrossRefGoogle Scholar
  14. 14.
    Fritzberg AR, Kasina S, Eshima D, Johnson DL (1986) J Nucl Med 27:111Google Scholar
  15. 15.
    Despopoulos A (1965) J Theor Biol 8:163CrossRefGoogle Scholar
  16. 16.
    United States Pharmacopoeia 28, 2005, NF 23, p 1009Google Scholar
  17. 17.
    United States Pharmacopoeia 28, 2005, NF 23, p 1895Google Scholar
  18. 18.
    Taylor AT, Lipowska M, Hansen L, Malveaux E, Marzilli LG (2004) J Nucl Med 45(5):885Google Scholar
  19. 19.
    Verbruggen AM, Nosco DL, Van Nerom CG, Bormans GM, Adnaens PJ, Dc Roo MJ (1992) J NucI Med 33:551Google Scholar

Copyright information

© Akadémiai Kiadó, Budapest, Hungary 2010

Authors and Affiliations

  • Amir Reza Jalilian
    • 1
  • Hassan Yousefnia
    • 1
  • Samaneh Zolghadri
    • 1
  • Mohammad Reza Khoshdel
    • 2
  • Fatemeh Bolourinovin
    • 2
  • Ali Rahiminejad
    • 2
  1. 1.Radiopharmaceutical Research and Development Lab (RRDL)Nuclear Science and Technology Research Institute (NSTRI)TehranIran
  2. 2.Agricultural, Medical and Industrial Research School (AMIRS)Nuclear Science and Technology Research Institute (NSTRI)KarajIran

Personalised recommendations